Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
--
P/B Ratio
0.43
Industry P/E
--
Debt to Equity
0.04
ROE
-1.79 %
ROCE
-167.79 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-22.62 Mln
EBITDA
$-24.32 Mln
Net Profit
$-24.79 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bluejay Diagnostics Inc (BJDX)
| -66.20 | -58.33 | -50.87 | -99.25 | -94.00 | -- | -- |
|
BSE Sensex
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Bluejay Diagnostics Inc (BJDX)
| -98.96 | -83.94 | -85.16 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 14.81 | 10,289.47 | 14.52 | 12.69 | |
| 68.96 | 9,766.86 | 94.68 | 2.52 | |
| 270.21 | 10,728.92 | 770.42 | 1.2 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation... using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts. Address: 360 Massachusetts Avenue, Acton, MA, United States, 01720 Read more
Principal Financial, Accounting & Executive Officer, President, CEO and Director
Mr. Indranil Dey
Principal Financial, Accounting & Executive Officer, President, CEO and Director
Mr. Indranil Dey
Headquarters
Acton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bluejay Diagnostics Inc (BJDX) stood at $ 7 Mln as on 31-Dec-24
The share price of Bluejay Diagnostics Inc (BJDX) is $1.65 (NASDAQ) as of 21-Apr-2025 15:43 EDT. Bluejay Diagnostics Inc (BJDX) has given a return of -94% in the last 3 years.
Bluejay Diagnostics Inc (BJDX) has a market capitalisation of $ 2 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Bluejay Diagnostics Inc (BJDX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bluejay Diagnostics Inc (BJDX) and enter the required number of quantities and click on buy to purchase the shares of Bluejay Diagnostics Inc (BJDX).
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts. Address: 360 Massachusetts Avenue, Acton, MA, United States, 01720
The CEO & director of Mr. Indranil Dey. is Bluejay Diagnostics Inc (BJDX), and CFO & Sr. VP is Mr. Indranil Dey.
There is no promoter pledging in Bluejay Diagnostics Inc (BJDX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,070
|
|
|
1,049
|
|
|
978
|
| Bluejay Diagnostics Inc (BJDX) | Ratios |
|---|---|
|
Return on equity(%)
|
-178.98
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bluejay Diagnostics Inc (BJDX) was $0 Mln.
$-0.33
(
